IPHA Stock Analysis: Buy, Sell, or Hold?
IPHA - Innate Pharma S.A. ADS
$2.26
0.17 (8.13%)
▲
5d:
+3.67%
30d:
+28.41%
90d:
+14.72%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Sep 17, 2026
23d
Get Alerted When IPHA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: IPHA shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: IPHA shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: IPHA is currently trading at $2.26, which is considered extended relative to its 30-day fair value range of $1.69 to $2.18.
Technical Outlook: Technically, IPHA is in a uptrend. Immediate support is located at $2.04, while resistance sits at $2.71. The stock is showing strong short-term momentum, up 8.1% recently.
Market Sentiment: IPHA scores 13/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $7.00 (+209.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, IPHA is in a uptrend. Immediate support is located at $2.04, while resistance sits at $2.71. The stock is showing strong short-term momentum, up 8.1% recently.
Market Sentiment: IPHA scores 13/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $7.00 (+209.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$1.69 -
$2.18
Company Quality Score
37/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
31.6%
All Signals
- BEARISH: Price extended above range
- BEARISH: Weak technical setup (13/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+8.1%)
- BULLISH: Trading 209.7% below Wall St target ($7.00)
- WARNING: Composite score 37/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.69 -
$2.18
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$2.04
Resistance Level
$2.71
Current Trend
Uptrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-3.58
Wall Street Target
$7.00
(+209.7%)
Revenue Growth (YoY)
-46.7%
Earnings Growth (YoY)
-74.7%
Share & Embed Analysis
Last updated: August 24, 2026 2:13 AM ET
Data refreshes hourly during market hours. Next update: 3:13 AM
Data refreshes hourly during market hours. Next update: 3:13 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is IPHA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$110 | 66 BUY |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$200 | 41 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$88 | 41 HOLD |
|
BHVN
Biohaven Ltd. |
STRONG BUY
16 analysts |
$23 | 49 HOLD |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$86 | 40 SELL |
